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Abstract: Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. 
Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared 
with dexamethasone alone in patients with relapsed or refractory MM (RRMM). Clinical benefit may be greatest when Len+Dex is 
given at first relapse, and continued treatment appears to provide greater depth of response and improved survival outcomes. The most 
common adverse events associated with Len+Dex are cytopenias, which are predictable and manageable. Len+Dex is associated with 
an increased risk of venous thromboembolism, which necessitates adequate prophylaxis. The risk of second primary malignancies does 
not appear to be increased in patients with RRMM treated with lenalidomide-based therapy. Here we review the safety and efficacy of 
Len+Dex in RRMM, and provide an overview of data from Spain on the use of Len+Dex in RRMM.
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Introduction
Multiple myeloma (MM) is one of the most   common 
hematological  malignancies.1,2  According  to  the 
European Network of Cancer Registries, MM affects 
approximately 21,500 people each year in Europe, 
with 15,000 dying from MM annually. In the USA, 
an estimated 20,200 people are diagnosed with MM 
each year, and approximately 10,700 die from MM 
annually.1 The disease primarily affects older adults 
(median age at diagnosis is approximately 70 years), 
and is characterized by clonal proliferation of malig-
nant plasma cells in the bone marrow, monoclonal 
protein in the blood or urine, and associated organ 
dysfunction.3
The goals of therapy for MM are to prolong overall 
survival (OS) by achieving durable remissions and to 
control disease symptoms.3 Intensive chemotherapy 
with  autologous  stem-cell  transplantation  (ASCT) 
is an effective treatment option, but few patients are 
eligible for this procedure due to advanced age and 
comorbidity. Although long-term disease control is 
possible, virtually all patients eventually relapse.4
The  introduction  of  the  novel  therapies 
  lenalidomide, thalidomide, and bortezomib has had 
a positive impact on survival outcomes in patients 
with  MM.5–7  Patients  treated  with  one  or  more  of 
these agents were found to have significantly longer 
survival than those who were never exposed to these 
agents.5 Lenalidomide, thalidomide, and bortezomib 
now  have  established  roles  in  the  management  of 
patients with MM, although ongoing studies continue 
to refine the optimal use of these agents with regard to 
combination, sequence, and duration of therapy.
Lenalidomide  is  an  orally  administered  immu-
nomodulatory  drug  that  is  structurally  related  to 
  thalidomide. It was originally developed to overcome 
some of the side effects associated with   thalidomide 
and provide more potent inhibition of tumor   necrosis 
factor-alpha.8  The  mechanism  of  action  of  lenali-
domide in MM is complex and involves both direct 
tumoricidal effects on MM cells and indirect effects 
on  the  bone  marrow  microenvironment  and  host 
  immunity;  together,  these  effects  inhibit  MM  cell 
growth and survival (Table 1).9 Specifically, lenalido-
mide has been shown to prevent growth and induce 
apoptosis in MM cells,10–12 interfere with MM cell 
adhesion  to  bone  marrow  stromal  cells,13  inhibit 
angiogenesis,14  and  boost  host  immunity  against 
MM cells.15–18 The activity of lenalidomide in MM is 
attributed to its ability to reduce the MM cell burden 
via its antiproliferative and proapoptotic effects while 
suppressing residual MM cell growth via its effects 
on the bone marrow microenvironment and immuno-
modulatory effects. The unique effects of lenalido-
mide may explain the additive antimyeloma effects 
observed when lenalidomide is combined with other 
active agents, such as dexamethasone, in vitro: for 
example, the caspase-8-mediated apoptosis induced 
by  lenalidomide  may  complement  the  caspase-9-
  mediated  signaling  induced  by  dexamethasone, 
resulting  in  greater  myeloma  cell  death;  however, 
dexamethasone appears to antagonize the immuno-
stimulatory effects of lenalidomide.10,12,19
Early clinical studies indicated that lenalidomide 
is active in patients with relapsed or refractory MM 
(RRMM),  including  those  who  had  received  prior 
thalidomide.13  Notably,  adverse  events  commonly 
associated  with  thalidomide,  such  as  somnolence, 
constipation, and neuropathy, were not observed. The 
addition of dexamethasone to lenalidomide treatment 
was  found  to  further  increase  response  rates.20  In 
two phase III placebo-controlled studies in patients 
with RRMM, the combination of lenalidomide plus 
dexamethasone  (Len+Dex)    significantly  increased 
Table 1. Mechanisms of action of lenalidomide.9
Direct tumoricidal effects on MM cells Indirect immunomodulatory effects inhibiting MM cell expansion
Antiproliferative effects Immunomodulation
  G0-G1 cell cycle arrest   Altering cytokine production
  Increased p21 expression   T cell activation
Proapoptotic effects   Augmentation of natural killer cell function
  enhanced TRAIL effects Inhibition of MM-BMSC adhesion
  Caspase-8 pathway activation Inhibition of proinflammatory cytokines
  Inhibition of NF-κB Antiangiogenic effects
Abbreviations: BMSC, bone marrow stromal cell; MM, multiple myeloma.
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response  rates  and  prolonged  progression-free  sur-
vival  (PFS)  and  OS,  compared  with  dexametha-
sone alone.21–23 The Len+Dex regimen was effective 
regardless of the type of prior therapy received24,25 and 
was effective in patients with renal impairment, pro-
vided that appropriate dose modifications are made.26 
Moreover, Len+Dex was found to be most effective 
when  given  at  first  relapse.27  Continued  treatment 
led to greater depth of response and improved sur-
vival outcomes.28,29 These data led to the approval of 
Len+Dex for the treatment of patients with MM who 
have received at least 1 prior therapy.30
As clinical experience with lenalidomide increases, 
more is learned about its long-term safety and effi-
cacy in MM. For example, recent findings from Spain 
suggest that lenalidomide is effective in MM patients 
with extramedullary plasmacytomas.31,32 The purpose 
of this article is to review the current understanding 
of the safety and efficacy of lenalidomide-based ther-
apy in the treatment of patients with RRMM, with a 
special focus on the Spanish experience (Alegre A, 
Oriol-Rocafiguera A, García-Laraña J, et al. Safety, 
efficacy, and quality-of-life of lenalidomide plus dex-
amethasone for the treatment of relapsed or refractory 
multiple myeloma: the Spanish experience. Submit-
ted to Leukemia and Lymphoma, 2011).31,33,34
Efficacy
The efficacy and safety of Len+Dex in RRMM was 
demonstrated in two pivotal phase III trials (MM-009 
and MM-010).21–23 Both studies compared Len+Dex 
with  placebo  plus  dexamethasone  in  patients  who 
had received at least one prior therapy. Lenalidomide 
was given orally at a dose of 25 mg per day on days 
1–21 of each 28-day cycle until disease progression. 
In both treatment groups, dexamethasone was given 
orally at a dose of 40 mg per day on days 1–4, 9–12, 
and 17–20 for the first four cycles. After the fourth 
cycle, dexamethasone was given on days 1–4 only of 
each cycle.
Both studies indicated that Len+Dex significantly 
improved response rates and time to progression com-
pared  with  placebo  plus  dexamethasone.21,22  These 
results were confirmed in a pooled analysis of data 
from both studies, which showed significant differ-
ences in response rates (61% vs. 22%; P , 0.001) and 
TTP (13.4 months vs. 4.6 months; P , 0.001), favor-
ing Len+Dex.23 With a median follow-up of 48 months 
for surviving patients, median PFS was significantly 
longer with Len+Dex (11.1 months vs. 4.6 months; 
P , 0.001) (Fig. 1A) and median OS was 38.0 months 
with Len+Dex and 31.6 months with placebo plus dex-
amethasone (P = 0.045) (Fig. 1B).23 The significant 
improvement in OS is notable because nearly half of 
the 351 patients assigned to placebo plus dexametha-
sone received lenalidomide-based therapy at the time 
of progression or unblinding of the study.
Several prespecified subanalyses of MM-009 and 
MM-010 data were performed to further define the 
activity of Len+Dex. These analyses confirmed that 
clinical benefit was observed regardless of whether 
patients had previously received thalidomide therapy.24 
Similarly, prior high-dose chemotherapy with ASCT 
did not affect the benefit of Len+Dex at relapse.25 The 
analyses also showed that Len+Dex was most effec-
tive when given at first relapse, rather than as a later 
line of therapy.27 The quality of response to Len+Dex 
improved over time, with 38% patients who had an 
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Figure  1.  Progression-free  survival  (A)  and  overall  survival  (B)  in 
patients  with  relapsed  or  refractory  multiple  myeloma  treated  with 
  combination  lenalidomide  and  dexamethasone  (Len+Dex)  or  placebo 
plus   dexamethasone (Placebo+Dex).
Reproduced with permission from Dimopoulos et al23 2009 Macmillan 
Publishers Ltd.
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initial documented partial response (PR) by cycle 6 
achieving complete response (CR) with continuous 
treatment. Furthermore, the achievement of CR or 
very good PR (VGPR) as best response was linked to 
improved OS, irrespective of when CR or VGPR was 
achieved.29 It was also shown that continuing treat-
ment until disease progression appears to improve 
OS.28 The promising effects of long-term lenalido-
mide therapy when used as maintenance therapy in 
patients with newly diagnosed MM35–37 provide fur-
ther support for prolonged use of lenalidomide-based 
therapy in RRMM.
Other studies conducted in a daily practice set-
ting have provided further evidence of the safety and 
efficacy of Len+Dex in RRMM. Two studies recently 
evaluated Len+Dex when given through compassion-
ate use programs in the Netherlands38 and Spain.33 In 
the Dutch Compassionate Use Program, 114 patients 
with  RRMM  received  Len+Dex.38  Patients  had 
received a median of 3 prior lines of therapy, and 
91% had received prior thalidomide. The response 
rate was 69%, including a CR rate of 6%. Notably, 
response  was  not  influenced  by  prior  thalidomide 
or bortezomib therapy. Median time to progression 
and median OS were 9 and 22 months, respectively. 
Grade 3 or higher hematologic adverse events were 
reported  in  37%  of  patients,  and  the  incidence  of 
venous thromboembolism (VTE) was low (5%) with 
appropriate thromboprophylaxis. Similar results were 
found in the Spanish Compassionate Use Registry, 
which is discussed in detail in the following sections. 
Results  from  the  Spanish  cohort  of  the  expanded 
access program (MM-018) on the long-term use of 
Len+Dex are also discussed (Alegre A, Oriol-Roca-
figuera A, García-Laraña J, et al. Safety, efficacy, and 
quality-of-life of lenalidomide plus dexamethasone 
for the treatment of relapsed or refractory multiple 
myeloma: the Spanish experience. Submitted to Leu-
kemia and Lymphoma, 2011).34
safety
The primary adverse events associated with Len+Dex 
in RRMM are cytopenias, VTE, rash, fatigue, and 
muscle cramps.23 In phase III trials, Len+Dex was 
associated  with  a  significantly  higher  incidence  of 
severe neutropenia, thrombocytopenia, anemia, and 
VTE compared with dexamethasone alone (Fig. 2).23 
Peripheral  neuropathy,  a  common  and  problematic 
side effect of thalidomide and bortezomib, is rarely 
observed with lenalidomide.23,39
Lenalidomide is not nephrotoxic, but it is excreted 
renally.30,40  Impaired  renal  function  can  delay 
clearance,  resulting  in  increased  drug    exposure. 
  Consequently, lower doses of lenalidomide may pro-
vide sufficient drug exposure in patients with renal 
impairment, and dose reductions are recommended 
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Figure 2. Grade 3 or higher adverse events occurring in more than 5% of patients with relapsed or refractory multiple myeloma treated with combination 
lenalidomide and dexamethasone (Len+Dex) or placebo plus dexamethasone (Placebo+Dex).
Note: *P , 0.05. 
Data from Dimopoulos et al.23
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for  these  patients.30,40  Among  the  353  patients 
who  were  treated  with  Len+Dex  in  the  MM-009 
and  MM-010  studies,  response  rates  were  com-
parable  in  patients  with  mild  or  no  renal  impair-
ment  (  creatinine  clearance  .60  ml/min;  64%), 
moderate  renal    impairment  (30–60  ml/min;  56%) 
or severe renal impairment (,30 ml/min; 50%).26 
  Moreover, renal function improved during Len+Dex 
treatment in 72% of patients who had   moderate or 
severe  renal  impairment  at  study  entry.  PFS  was 
similar  in  all  groups  according  to  renal    function. 
  Compared with patients with mild or no renal impair-
ment, those with severe renal impairment were more 
likely to experience thrombocytopenia, to require lenali-
domide dose reductions, and to have shorter OS.
Managing myelosuppression
Neutropenia and thrombocytopenia are common in 
patients treated with Len+Dex but their occurrence 
is  predictable  and  manageable.23,40,41  Guidelines  on 
management  of  cytopenias  during  lenalidomide 
therapy have been developed.30,40 Generally, neutro-
penia and thrombocytopenia can be managed with 
a combination of growth factor support or platelet 
transfusions, and lenalidomide dose modifications or 
discontinuation.
Managing vTe risk
Like thalidomide, lenalidomide is associated with a 
low risk of VTE when given as monotherapy.42 When 
combined with other agents, such as dexamethasone, 
however, the risk of VTE increases.42–44 The risk can 
be  reduced  by  administering  thromboprophylaxis. 
Patients  treated  with  Len+Dex  should,  therefore, 
receive  appropriate  thromboprophylaxis  based  on 
their individual risk status.40,44 A recent randomized 
trial  compared  three  forms  of  thromboprophylaxis 
(aspirin, fixed low-dose warfarin, or a low-  molecular-
weight heparin [LMWH]) in patients with MM treated 
with thalidomide. It showed that aspirin and warfarin 
were as effective as the LMWH in reducing the risk 
of VTE; in elderly patients, warfarin was less effec-
tive than the LMWH.45
Second primary malignancies
Recently,  concerns  have  been  raised  regarding  the 
risk of second primary malignancy (SPM) following 
treatment  with  lenalidomide.  Reports  of  increased 
risk of developing SPM have been generated from 
trials evaluating lenalidomide as first-line therapy or 
as maintenance therapy following ASCT in patients 
with  newly  diagnosed  MM.37,46–48  In  patients  with 
RRMM, an increased risk of SPM has not been cur-
rently demonstrated.49,50 An analysis of pooled data 
from the MM-009 and MM-010 studies indicated that 
SPM incidence was low in both treatment groups, and 
similar  to  expected  background  incidence  accord-
ing to the US Surveillance, Epidemiology, and End 
Results (SEER) cancer registries.49 A pooled analysis 
assessed data from 3839 patients treated with lenali-
domide-based therapy in 11 clinical trials, including 
313  patients  (8%)  who  received  lenalidomide  for 
24 months or more.50 No significant increase in inci-
dence rates of SPM were found compared with inci-
dence rates reported in the SEER registries. Thus, at 
this time, an increased risk of SPM has not been dem-
onstrated in patients with RRMM treated with lenali-
domide-based therapy, even with long-term therapy. 
Ongoing studies will continue to help determine the 
risk of SPM.
The Spanish Experience
Spanish Compassionate Use Registry
Lenalidomide  was  approved  for  the  treatment  of 
patients  with  RRMM  in  Spain  in  January  2008.33 
Access to the drug prior to that time was possible 
through  a  compassionate  use  program  for  those 
patients with RRMM and no other treatment options. 
We  conducted  a  nationwide  cross-sectional  retro-
spective  study  of  111  patients  with  RRMM  who 
received lenalidomide through the Spanish Compas-
sionate  Use  Registry.33  Baseline  characteristics  are 
summarized in Table 2.33 Patients had advanced dis-
ease (median disease duration 37.4 months [range, 
4–200  months])  and  had  received  a  median  of  3 
prior lines of therapy (range, 1–8). Fourteen patients 
(12.6%) had renal failure, defined as creatinine levels 
greater than 177 µmol/L. Approximately 61% had 
multiple lytic lesions, 24% had extramedullary plas-
macytomas, and 17% had cytogenetic abnormalities. 
Most patients (90%) had received prior bortezomib, 
26% had received prior thalidomide, and 35% had 
undergone high-dose chemotherapy with ASCT.
Approximately 90% of patients received Len+Dex. 
In 80% of patients, lenalidomide was administered 
according to the standard schedule: 25 mg per day 
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for  the  first  3  weeks  of  each  4-week  cycle.  The 
remaining patients received less intensive doses and 
schedules. Among the 14 patients with renal failure 
at  baseline,  5  received  the  standard  schedule  and 
8 were given lenalidomide at a dose of 25 mg per 
day for 3 days per week for the first 3 weeks of each 
4-week cycle; 1 patient received lenalidomide at a 
dose of 15 mg per day for the first 3 weeks of each 
4-week cycle.
In this heavily pretreated group of patients, the 
overall response rate was 66%, which is comparable 
to results from phase III trials evaluating Len+Dex 
(Table 3).23 Notably, the overall response rate was 
also high in patients with renal failure (54%), which 
is also comparable to findings from phase III trials,26 
Table 2. Disease characteristics, prior therapy, and lenalidomide dose and schedule in 111 patients with relapsed or 
  refractory multiple myeloma.33
Parameter All patients (n = 111) Renal failure* (n = 14)
Disease characteristics
  Duration of disease, median (range), months 37.4 (4–200) 32.9 (6–101)
  Cytogenetic abnormalities, n/N (%) 18/105 (17.1) 0
  extramedullary plasmacytomas, n (%) 27 (24.3) 3 (21.4)
  Multiple lytic lesions, n/N (%) 59/97 (60.8) 6/11 (54.5)
Prior therapy
  Number of prior therapies, median (range) 3.0 (1–8) 2.5 (1–5)
  Prior ASCT, n (%) 39 (35.1) 4 (28.6)
  Prior bortezomib, n (%) 100 (90.1) 11 (78.6)
  Prior thalidomide, n (%) 29 (26.1) 3 (21.4)
Lenalidomide treatment, n (%)
    Standard schedule (25 mg/day for the first 3 weeks  
  of a 4-week cycle)
89 (80.2) 5 (35.7)
    25 mg/day for 3 days per week for the first 3 weeks  
  of a 4-week cycle
10 (9.0) 8 (57.4)
  Other low-intensity schedules 9 (8.1) 1 (7.1)
Note: *Defined as creatinine .177 µmol/L.
Abbreviation: ASCT, autologous stem-cell transplantation.
although the depth of response was not as good as that 
achieved in the total population (Fig. 3). Overall, the 
median time-to-progression of 13.0 months was sim-
ilar to that achieved in phase III trials, but the median 
OS of 17.4 months was lower than that achieved in 
phase III trials (38 months), which may reflect the 
more advanced condition of patients receiving treat-
ment on a compassionate use basis. Adverse events 
consisted primarily of myelosuppression and were 
generally predictable and manageable. Most patients 
(87%) received some form of thromboprophylaxis, 
and the subsequent incidence of deep-vein thrombo-
sis was low (,2%).
These data generally support the findings from the 
registrational  phase  III  trials  evaluating  Len+Dex  in 
Table 3. Efficacy outcomes with Len+Dex in the Spanish Compassionate Use Registry33 and the phase III MM-009/010 trials.23
Parameter Compassionate use (n = 103) MM-009/010 (n = 353)
Overall response (partial response or better), % 66.0 60.6
  Complete response, % 14.6* 15.0
  very good partial response, % 10.7 17.3
  Partial response, % 40.8 28.3
Median time to progression, months 13.0 13.4
Median duration of response, months NA 15.8
Median progression-free survival, months NA 11.1
Median overall survival, months 17.4 38.0
Note: *Includes 4 patients (4%) with stringent complete response.
Abbreviation: NA, not available.
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patients with RRMM.21–23 The median survival time in 
our study was somewhat shorter than that reported in the 
phase III trials, which may reflect the more advanced 
disease state of patients who received lenalidomide on a 
compassionate use basis. The findings from the Spanish 
Compassionate  Use  Registry,  therefore,  complement 
the existing clinical trial data by providing further evi-
dence of the efficacy and safety of lenalidomide when 
given outside the context of a clinical trial.
MM-018 Spanish cohort
Recently, data were presented on the Spanish cohort 
of patients who participated in an expanded access 
program  for  lenalidomide  (MM-018)  (Alegre  A, 
Oriol-Rocafiguera A, García-Laraña J, et al. Safety, 
efficacy, and quality-of-life of lenalidomide plus dex-
amethasone for the treatment of relapsed or refrac-
tory  multiple  myeloma:  the  Spanish  experience. 
Submitted to Leukemia and Lymphoma, 2011).34 The 
MM-018 study was a multicenter, single-arm, open-
label study that evaluated safety and quality of life in 
patients with RRMM treated with Len+Dex.51 A total 
of 587 patients were enrolled in one of three geographic 
cohorts  (Spain,  UK/Ireland,  or  Austria/  Australia). 
The Spanish cohort consisted of 63 patients with a 
median age of 62 years. Approximately half of the 
patients received 12 or more cycles of Len+Dex. The 
response rate was 78%, including a CR rate of 21%. 
The median duration of response was 18.4 months, 
and the depth of response appeared to improve with 
prolonged therapy.
The safety profile in the Spanish cohort was gen-
erally consistent with that observed in the total study 
population (Table 4)34,51 and reports from previous 
trials:  the  primary  adverse  events  were  myelosup-
pression  and  deep-vein  thrombosis.  Health-related 
quality  of  life  was  assessed  at  baseline  and  after 
6 months of treatment using the European Organiza-
tion for Research and Treatment of Cancer Quality of 
Life Questionnaire for patients with cancer (EORTC 
QLQC30)  and  the  EORTC  QLQ  for  patients  with 
myeloma  (EORTC  QLQ  MY-20). While  scores  in 
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Figure  3.  Response  rates  to  lenalidomide-based  therapy  in  patients 
with  advanced  and  heavily  pretreated  relapsed  or  refractory  multiple 
myeloma. Renal failure defined as creatinine .177 µmol/L.
Data from Alegre et al.33
Abbreviations:  CR,  complete  response;  PR,  partial  response;  sCR, 
stringent CR; SD, stable disease; vGPR, very good PR.
Table 4. Key safety and quality-of-life outcomes following Len+Dex treatment in the MM-018 study total population51   
and Spanish cohort.34
Parameter Total population (n = 587) Spanish cohort (n = 63)
Median age, years 65 62
Hematologic events, grade $3, % 46 64
  Neutropenia 35 51
  Febrile neutropenia 4 6
  Thrombocytopenia 15 17
  Anemia 14 18
Deep vein thrombosis, all grades, % 6 8
New-onset peripheral neuropathy,  
  grade $3, %
,1 2
eORTC QLQ C30 No significant change (.5 points)  
in median scores from baseline in  
14 of 15 scales
Clinically meaningful improvement in scores 
for global QoL, fatigue, pain, and emotional, 
physical, role, social, and cognitive function
eORTC QLQ MY-20 No significant change (.5 points)  
in median scores from baseline
No significant change from baseline for  
all scales, except significant improvement  
in future-perspective scores
Abbreviations: eORTC QLQ C30, european Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with cancer; 
eORTC QLQ MY-20, eORTC QLQ for patients with myeloma; QoL, quality of life.
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the total study   population indicated that quality of 
life  was  maintained  during  24  weeks  of  treatment 
with Len+Dex, scores in the Spanish cohort revealed 
marked patient-reported improvement in nearly all 
EORTC QLQ C30 scales, including global quality 
of  life,  fatigue,  pain,  and  emotional,  physical  and 
cognitive function. The EORTC QLQ MY-20 results 
showed a meaningful improvement in future perspec-
tive scores.
Plasmacytomas
Extramedullary  disease  does  not  respond  to 
thalidomide,52,53 but some reports indicate that it is sensi-
tive to bortezomib.54–56 There is evidence that Len+Dex 
is also active in patients with RRMM and plasmacy-
tomas,  including  extramedullary  plasmacytomas.31–33 
In the Spanish Compassionate Use Registry, 8 of 24 
patients  (33%)  with  extramedullary  plasmacytoma 
responded  to  lenalidomide-based  therapy,  includ-
ing 4 patients (17%) who had a CR.33 In a case report 
recently  presented  by  García  Pérez,32  11  cycles  of 
Len+Dex were given to a 62-year-old woman with 
RRMM  who  had  developed  a  large  extramedullary 
plasmacytoma. Reduction in plasmacytoma size was 
seen  after  the  third  cycle.  The  patient  continues  to 
receive lenalidomide monotherapy at a dose of 10 mg 
per day. Lastly, in a prospective study of 18 patients 
with  extramedullary  plasmacytomas,  lenalidomide-
based  therapy  was  found  to  induce  a  response  at 
extramedullary sites in 11 patients (61%),31 including 
complete disappearance of extramedullary disease in 
8 patients (44%). Notably, all 18 patients had received 
prior  bortezomib,  and  all  had  relapsed  (n  =  12)  or 
refractory disease (n = 6) following their last therapy. 
These findings suggest that lenalidomide may be more 
effective than thalidomide and at least as effective as 
bortezomib in the treatment of RRMM with extramed-
ullary disease, although larger prospective studies are 
needed to confirm these preliminary results.
Summary
Len+Dex prolongs PFS and OS in RRMM and has 
become a standard treatment option for patients who 
have received at least 1 prior therapy. Evidence sug-
gests that Len+Dex is beneficial regardless of prior 
thalidomide exposure or prior ASCT. Len+Dex may be 
most beneficial when given at first relapse.   Continued 
treatment appears to be associated with greater depth 
of response resulting in improved survival   outcomes. 
The primary adverse events associated with Len+Dex 
in RRMM are myelosuppression and VTE; other com-
mon adverse effects include rash, fatigue, and muscle 
cramps. Lenalidomide does not appear to cause or 
exacerbate peripheral neuropathy. The risk of SPM 
continues  to  be  investigated,  particularly  in  newly 
diagnosed patients. In patients with RRMM, lenalido-
mide-based therapy does not appear to be associated 
with an increased incidence of SPM; the risk of SPM, 
therefore, does not appear to outweigh the potential 
benefits of treatment. The Spanish experience with 
Len+Dex in RRMM supports the findings from large 
clinical  trials  indicating  that  Len+Dex  is  effective 
and has a predictable and manageable safety profile. 
Moreover, data from the Spanish Compassionate Use 
Registry suggest that Len+Dex can be given safely 
and effectively to heavily pretreated patients with very 
advanced disease in a daily practice setting.
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